Elicit: IL-17A Inhibition in Plaque Psoriasis

IL-17A Inhibition in Plaque Psoriasis

How does IL-17A inhibition affect inflammatory pathways in plaque psoriasis?

IL-17A inhibition produces rapid and comprehensive suppression of inflammatory pathways in plaque psoriasis by interrupting the IL-23/Th17 axis and neutrophil-keratinocyte crosstalk, achieving nearly complete pathway normalization within 12 weeks.

Abstract

IL-17A inhibition produces rapid, comprehensive, and sustained effects on inflammatory pathways in plaque psoriasis. Across 10 studies examining secukinumab, ixekizumab, and AIN457 in moderate-to-severe disease, pathway suppression begins within 1 week of treatment, with clearance of cutaneous neutrophils and normalization of keratinocyte abnormalities evident by 2 weeks. The magnitude of effect increases progressively, achieving 89-97% resolution of psoriasis-associated expression differences by 12 weeks and sustained suppression through 52 weeks. IL-17A functions as a critical node within the IL-23/Th17 axis, with its inhibition producing cascading effects that include reductions in upstream IL-23, downstream targets like beta-defensin2, and complete depletion of IL-17-producing T cell populations.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

n = 200
Papers screened using various criteria related to patient population, intervention, outcomes, study design, treatment duration, and confounding factors.
n = 200 Papers screened out
n = 190 Papers included for extraction

Data extraction details

IL-17A Treatment: Extract details about the IL-17A inhibition intervention used in plaque psoriasis patients.
Inflammatory Pathway Assessment: Extract information about how inflammatory pathways were measured.
Pathway Effects: Extract the observed effects of IL-17A inhibition on inflammatory pathways in plaque psoriasis.
Mechanistic Insights: Extract mechanistic understanding of how IL-17A inhibition affects inflammatory pathways.
Study Design: Extract study design elements relevant to assessing inflammatory pathway effects.
Patient Population: Extract characteristics of the plaque psoriasis patient population relevant to inflammatory pathway assessment.

Results

Characteristics of Included Studies

This systematic review included 10 studies examining the effects of IL-17A inhibition on inflammatory pathways in plaque psoriasis. The studies utilized three IL-17A inhibitors: secukinumab (6 studies), ixekizumab (2 studies), and AIN457 (1 study).

Study	Full text retrieved?	Study type	IL-17A inhibitor	Dosage/route	Treatment duration	Sample size	Control group	Patient severity
J. Krueger et al., 2019	Yes	RCT	Secukinumab	300 mg SC	Up to 52 weeks	24 secukinumab, 12 placebo	Placebo	Moderate-to-severe
J. Krueger et al., 2012	No	Phase I RCT	Ixekizumab	5-150 mg SC	6 weeks	40 subjects	Placebo	Not specified
...	...	...	...	...	...	...	...	...

Assessment Methods for Inflammatory Pathways

Studies employed diverse methodologies to evaluate inflammatory pathway changes following IL-17A inhibition.

Study	Sample types	Measurement techniques	Inflammatory markers assessed	Pathway focus	Assessment timepoints
J. Krueger et al., 2019	Skin biopsies	Transcriptomics, IHC	IL-23, IL-17A, beta-defensin2	Th17, innate immunity	Weeks 1, 4, 12, 52
J. Krueger et al., 2012	Skin lesions	RT-PCR, microarrays	IL-17A, TNF-α	Th17 pathway	Weeks 2, 6
...	...	...	...	...	...

Effects of IL-17A Inhibition on Inflammatory Pathways

Timeline of Pathway Changes

IL-17A inhibition induced rapid and sustained changes in inflammatory pathways across all studies examined.

Study	Week 1-2 effects	Week 4-6 effects	Week 12+ effects	Statistical significance
J. Krueger et al., 2019	Suppression of IL-23/IL-17 axis evident; reductions in IL-23, IL-17A, beta-defensin2	Continued suppression	Sustained suppression through week 12; continued effects at week 52	q < 0.05
...	...	...	...	...

Mechanistic Insights into IL-17A Pathway Effects

Cell-Type Specific Effects

IL-17A inhibition affected multiple cellular compartments within psoriatic skin, showing differential timing and magnitude of effects.

Neutrophils: Rapid clearance within 2 weeks of treatment. IL-17A inhibition interrupts neutrophil-keratinocyte crosstalk.

Keratinocytes: Early reduction of IL-17A-dependent transcripts synthesized by hyperplastic keratinocytes favored plaque resolution.

T cells: Significant reductions in T cell infiltration into dermis and epidermis were observed across multiple studies.

Dendritic cells: Effects on dendritic cell populations were more delayed, with an increase in immunosuppressive markers.

Synthesis

The reviewed studies consistently demonstrate that IL-17A inhibition produces rapid, comprehensive, and sustained effects on inflammatory pathways in plaque psoriasis. This inhibition shows differential cellular targets affected over time and a comparative analysis of how IL-17A inhibition differs from IL-23 inhibition.